KRAS and non-small cell lung carcinoma: Another trial (NCT02276027) reported an overall response rate (9.1%) in advanced NSCLC patients treated with binimetinib monotherapy, with tumors harboring KRAS, NRAS, or BRAF mutations not showing satisfactory responses.